Inhibition of 12/15-LOX hyperactivation mitigates cognitive decline in a chronic cerebral hypoperfusion mouse model and in H2O2-induced HT22 cells: therapeutic effects of brozopine

Brozopine (BZP), a novel inhibitor of 12/15-lipoxygenase (12/15-LOX), has previously demonstrated efficacy in mitigating inflammatory and oxidative stress-related injury in cerebral ischaemia models. This study aimed to evaluate the therapeutic potential and underlying mechanisms of BZP in a mouse m...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xuening Wang, Zhizai Lu, Qiuji Shao, Yi Wang, Zixin Zhang, Zhiyu Wang, Qingran Jia, Jinpeng Zhu, Yiran Song, Lingxu Yuan, Yiming Wang, Shaoyang Xu, Lirou He, Junbiao Chang, Yuan Gao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2025-12-01
coleção:	Journal of Enzyme Inhibition and Medicinal Chemistry
Assuntos:	BZP 12/15-LOX inflammation CCH cognitive decline
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/14756366.2025.2547259
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!